Novartis Execs Highlight Cosentyx, LCZ696 As Key 2015 Launches
This article was originally published in The Pink Sheet Daily
Executive Summary
The swapping of product portfolios with other companies remains on track at Switzerland’s big pharma Novartis, despite a seven-percentage-point sales erosion due to emerging generic competition during 2014, and more recent currency turmoil in its home country.